Singapore-based Nanyang Biologics (NYB) has entered a business combination agreement valued at $1.5 billion with Nasdaq-listed special purpose acquisition company RF Acquisition Corp II. NYB combines machine learning with natural compound libraries to innovate drug discovery, boasting one of the world’s largest AI-curated collections of bioactive compounds. The deal positions NYB to advance a pipeline including preclinical candidates for HRD-positive cancers, cardiovascular, and mental health conditions. The transaction is expected to close by Q2 2026, marking a significant move for AI-driven drug discovery in Asia.